Research Papers:

Overexpression of OCT4 is associated with gefitinib resistance in non-small cell lung cancer

Bin Li, Zhouhong Yao, Yunyan Wan and Dianjie Lin _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:77342-77347. https://doi.org/10.18632/oncotarget.12999

Metrics: PDF 1583 views  |   HTML 1701 views  |   ?  


Bin Li1, Zhouhong Yao1, Yunyan Wan1, Dianjie Lin1

1Department of Respiratory Medicine, Shandong Provincial Hospital Affiliated to Shandong University, Shandong University, Jinan, Shandong, China, 250021

Correspondence to:

Dianjie Lin, email: [email protected]

Keywords: NSCLC, chemoresistance, OCT4, gefitinib, proliferation, apoptosis

Received: August 15, 2016     Accepted: October 14, 2016     Published: October 31, 2016


Epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors (TKIs) have emerged as first-line drugs for non-small cell lung cancers (NSCLCs). However, the resistance to TKIs represents the key limitation for their therapeutic efficacy. We found that the difference of OCT4 expression between NSCLC and the adjacent non-tumourous tissues was statistically significant. Knockdown of OCT4 in NSCLC cells could decrease cell proliferation, and potentiate apoptosis induced by gefitinib, suggesting OCT4 may contribute to gefitinib resistance in NSCLC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12999